EN DE
Watch Mesa Laboratories Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mesa Laboratories Inc (MLAB) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Mesa Laboratories Inc stock $52.78, price $128, that is 58.8% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Technology US

ML Mesa Laboratories Inc logo Broad data Nov 7, 2026

Mesa Laboratories Inc

MLAB · US
Solid, but very expensive

Our calculation puts a fair price 59% below what the stock costs today.

Healthy Growth (revenue 5y +13.2 %/yr in USD)
Generates free cash flow
0.5% dividend yield · Sustainable
Broad data
Quality 56/100
Thin margins · 1.9% net margin (TTM)
Moderate debt
Insiders bought $902,411 (6M) · sold $1.6M
Costs 151 times its yearly profit.
Fair value $52.78 · Strongly overvalued (−58.8%)
Trails peers (3/13)
Narrow moat 36/100 · thin data
Quality growth
Watch Mesa Laboratories Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$324.08 $56.93 Fair Value $52.78 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $56.93 – $324.08 · fair‑value band $44.52 – $65.98 · the $128.25 price screens above the $52.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Mesa Laboratories in your weekly email

Every Wednesday you see whether Mesa Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.

Show moreShow less

The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.

This segment also provides testing and laboratory services to the dental and pharmaceutical industries.

Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research.

The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides.

Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments.

This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands.

Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Stock analysis

Mesa Laboratories Inc (MLAB) currently trades at $128.25, while our model-based Fair Value estimate is $52.78, 59% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $89.16 per share, and 1 of the 22 models we run sit above the $128.25 price.

Bear case: the Dividend Discount group reads lowest at $8.07, and 21 of the 22 models stay below the price. Data coverage for this calculation is high.

Scenario range: $44.52 (bear) to $65.98 (bull), the price of $128.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Technology sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Mesa Laboratories Inc reported revenue of $249M in FY2026 versus $184M in FY2022, a compound +7.8%/yr. Reported net income was $6.7M in FY2026, compounding +37.6%/yr from FY2022.

Key figures

Market cap $738M Small · P/E ratio 150.9 · P/S ratio 2.96 · EPS (TTM) $0.8500 · Dividend yield 0.5% · Net margin 1.9% · Return on equity 2.7% · Return on assets (EBIT) −10.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 83% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Technology peers we cover trades at −45% fair-value upside, at −59%, MLAB screens richer than that median.

Fair Value models

Bear $44.52 Fair Value $52.78 Bull $65.98
Price $128.25 · Downside -58.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.1277 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $67.95 $131.35 $230.15 77
Growth DCF $65.92 $120.02 $198.17 76
Residual Income $22.26 $22.12 $22.91 76
All 24 models by family
DCF Models
FCF DCF $67.95 $131.35 $230.15 77
Owner Earnings $34.25 $73.70 $135.18 72
5Y Revenue Exit $30.52 $57.89 $93.21 70
5Y EBITDA Exit $57.08 $113.99 $185.60 73
5Y P/E Exit $23.35 $42.73 $63.63 69
10Y Revenue Exit $43.16 $73.02 $116.05 65
10Y EBITDA Exit $60.02 $110.48 $187.19 66
10Y P/E Exit $39.70 $62.91 $93.28 63
Earnings-Based
Graham-Dodd $8.16 $41.28 $57.01 64
Lynch FV $11.21 $16.01 $20.82 61
PEG = 1.0 $11.21 $16.01 $20.82 57
EPV n/a n/a $1.48 68
Dividend Discount
Gordon GGM $4.75 $8.39 $11.35 68
DDM Multi-Stage $4.75 $7.75 $8.98 67
Multiples
P/E Multiple $19.79 $26.39 $32.99 63
P/S Multiple $15.29 $20.39 $25.49 58
EV/EBIT $16.82 $30.88 $44.94 63
EV/EBITDA $53.04 $79.17 $105.31 66
EV/Revenue $4.74 $17.65 $30.55 49
Growth DCF
Growth DCF $65.92 $120.02 $198.17 76
Rev-Margin DCF $30.52 $58.30 $95.27 70
Economic Profit
Residual Income $22.26 $22.12 $22.91 76
ROIC Compounder n/a n/a $1.48 68
Growth Earnings
Growth-Adj P/E $17.43 $24.90 $32.37 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 82
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 35
How calm the share price moves, does not count
Price momentum 83
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 90
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $902,411, most recently on Aug 13, 2026. Over the same period, 4 people sold shares worth $1.6M. Buying cluster

  • BuyR Tony TripenyDirector2× since Mar 10, 2026: 2,215 shares, avg. $91.31$202,261Aug 13, 2026
  • BuySiddhartha KadiaPresident and CEO7,093 shares at $112.80$800,090Aug 13, 2026
  • SaleJohn James SullivanDirector7,093 shares at $112.80$800,090Aug 13, 2026
  • SaleJohn SakysCFO2× since Jun 16, 2026: 4,050 shares, avg. $93.05$376,870Jun 22, 202610b5-1 plan
  • SaleBrian David ArchboldSVP Operations2× since Jun 16, 2026: 3,667 shares, avg. $93.19$341,744Jun 22, 2026
  • SaleLyndsey Elizabeth CrennenCAO2× since Jun 16, 2026: 560 shares, avg. $91.98$51,509Jun 22, 2026
  • BuyMark Christopher CaponeDirector1,301 shares at $76.35$99,331Mar 10, 2026
  • BuyShiraz Shabanali LadiwalaDirector3,500 shares at $72.23$252,805Mar 10, 2026

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Start year 2021 (pandemic). Over 10 years: +11.4% a year
Revenue growth 38 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +23.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +23.4%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 23.4% / −8.7%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 7%
⚠ Base effect: the rate starts in the earnings trough around 2021 (starting value 0.41 per share, median 2.38 in 2016 to 2019). It measures the recovery from the trough, not lasting growth.

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.6% a year for the price.

MLAB screens overvalued: fair value 59% below the price. Compare with Keysight Technologies, Inc →

Compare Mesa Laboratories Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Scientific & Technical Instruments · 161 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 56 · Below median
Fair Value upside −58.8% · Below median
Profitability
Return on equity (12 months) 2.7% · Below median
Return on assets 1.6% · Below median
Net margin (12 months) 1.9% · Below median
Operating margin (12 months) 11.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 1.0% · Below median
Dividend yield (12 months) 0.5% · Below median
Balance sheet
Debt / equity 0.78× · Highest 25%

Valuation Multiplesvs Scientific & Technical Instruments median · lower = cheaper

P/E (12 months) 150.9× · Priciest 25%
P/B 3.96× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.96× · Cheaper than median
Price / free cash flow (fiscal year) 18.7× · Cheaper than median
EV/EBITDA 18.9× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)5 · sector 47
PAST (return on equity)11 · sector 24
HEALTH (low debt)61 · sector 99
DIVIDEND (yield)10 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Garmin Ltd GRMN $285.57 $314.13 +10% vs MLAB
Teledyne Technologies Incorporated TDY $618.60 $650.89 +5% vs MLAB
MKS Inc MKSI $192.27 $194.50 +1% vs MLAB
Cognex Corporation CGNX $47.78 $38.10 −20% vs MLAB
Fortive Corporation FTV $65.37 $35.67 −45% vs MLAB
Trimble Inc TRMB $54.11 $29.48 −46% vs MLAB
Chroma ATE Inc 2360 1,205 TWD 607.12 TWD −50% vs MLAB
Coherent Corp COHR $192.81 $92.93 −52% vs MLAB
Keysight Technologies, Inc KEYS $272.13 $117.27 −57% vs MLAB
AVIC Chengdu Aircraft Company 302132 ¥70.00 ¥12.60 −82% vs MLAB

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mesa Laboratories Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mesa Laboratories Inc Fair Value". https://www.fairvalue-calculator.com/stock/MLAB

Frequently asked questions

Is Mesa Laboratories Inc (MLAB) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $52.78 versus a price of $128.25, about 59% lower (overvalued).
What is the fair value of MLAB?
Our model-based fair value for Mesa Laboratories Inc is $52.78 (as of Nov 7, 2026), built from audited fundamentals. The current price: $128.25.
What is the quality score of MLAB?
Mesa Laboratories Inc has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mesa Laboratories Inc (MLAB)?
Our model-based price target is the fair value of $52.78 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario $44.52, optimistic scenario $65.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Mesa Laboratories Inc stock forecast for 2026?
Our models put fair value at $52.78, about 59% lower versus a price of $128.25 (overvalued). Cautious scenario $44.52, optimistic scenario $65.98. The calculation is refreshed regularly with new filings.
What is the revenue of Mesa Laboratories Inc (MLAB)?
Mesa Laboratories Inc reported trailing-twelve-month revenue of about $250M (latest available figure, as of Nov 7, 2026).
Does Mesa Laboratories Inc pay a dividend?
Mesa Laboratories Inc currently shows a dividend yield of 0.50% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Mesa Laboratories Inc (MLAB) and when is the ex-dividend date?
Mesa Laboratories Inc pays a dividend of $0.64 per share a year, a dividend yield of 0.5%. The next ex-dividend date is Nov 30, 2026, with payment on Dec 15, 2026. A dividend has been paid every year since at least 2003. The payout ratio is 75.3% of earnings. Free cash flow covers the dividend 11.05 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Mesa Laboratories Inc (MLAB)?
For today's price to be fair in a discounted-cash-flow model, Mesa Laboratories Inc would have to grow free cash flow by +15.3 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of MLAB use?
Our models discount Mesa Laboratories Inc at 11.4 %: a base by market capitalisation (small), damped by beta 1.05, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Mesa Laboratories Inc that is +15.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Mesa Laboratories Inc (MLAB) delivered so far?
Over the past 5 years revenue at Mesa Laboratories Inc grew +13.2 % a year. The price currently implies free-cash-flow growth of +15.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Mesa Laboratories Inc (MLAB) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Mesa Laboratories Inc (+15.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Mesa Laboratories Inc (MLAB)?
The free-cash-flow yield on the price is 5.36 %: that much free cash flow Mesa Laboratories Inc produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Mesa Laboratories Inc (MLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mesa Laboratories Inc it is $52.78 per share (as of Nov 7, 2026), against a price of $128.25. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Mesa Laboratories Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, MLAB trades above its calculated fair value: price $128.25, fair value $52.78, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MLAB?
No. The price is what the market pays today ($128.25); the fair value is what the company's own numbers justify ($52.78). For Mesa Laboratories Inc the two are $75.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mesa Laboratories Inc worth?
The market values Mesa Laboratories Inc at about $738M (market capitalisation, as of Nov 7, 2026). Per share that is $128.25; our models calculate a fair value of $52.78 per share.
What do the bullish and bearish scenarios say about MLAB?
Our models span a range for Mesa Laboratories Inc: cautious scenario $44.52, base $52.78, optimistic $65.98 per share (as of Nov 7, 2026, price $128.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MLAB?
Mesa Laboratories Inc trades at a price-to-earnings ratio of 150.9 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $52.78 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2026), reported earnings: 381.1. Other multiples: P/B 4.0, P/S 3.0, EV/EBITDA 18.9.
How solid is the balance sheet of Mesa Laboratories Inc (MLAB)?
Balance-sheet figures for Mesa Laboratories Inc (as of Nov 7, 2026): return on equity 2.7%, debt of 0.78 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is MLAB from its 52-week high?
Mesa Laboratories Inc trades at $128.25, about 10% below its 52-week high of $142.23 and 83% above the low of $70.15 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $52.78 is for.
Which stocks are comparable to Mesa Laboratories Inc?
From the same area (Technology) we also value Keysight Technologies, Inc, Garmin Ltd, Coherent Corp, Teledyne Technologies Incorporated, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mesa Laboratories Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $128.25, calculated fair value $52.78 (−59%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MLAB calculated?
We run Mesa Laboratories Inc through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $52.78 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Mesa Laboratories Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mesa Laboratories Inc (MLAB)?
The closing price on Nov 6, 2026 was $128.25. Our model-based fair value is $52.78, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mesa Laboratories Inc right now?
The price sits above even our optimistic bull case ($65.98). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Mesa Laboratories Inc

How large is the market capitalisation of Mesa Laboratories Inc (MLAB)?
The market capitalisation of Mesa Laboratories Inc is $738M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mesa Laboratories Inc (MLAB)?
The price-to-sales ratio of Mesa Laboratories Inc is 2.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mesa Laboratories Inc (MLAB)?
Earnings per share at Mesa Laboratories Inc are $0.8500 (price ÷ EPS = P/E 150.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mesa Laboratories Inc (MLAB)?
The dividend yield of Mesa Laboratories Inc is 0.5% (payout 75.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mesa Laboratories Inc (MLAB)?
The net margin of Mesa Laboratories Inc is 1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mesa Laboratories Inc (MLAB)?
The return on equity (ROE) of Mesa Laboratories Inc is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mesa Laboratories Inc (MLAB)?
On an EBIT basis the return on assets of Mesa Laboratories Inc is −10.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mesa Laboratories Inc (MLAB)?
The operating margin of Mesa Laboratories Inc is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mesa Laboratories Inc (MLAB)?
Revenue at Mesa Laboratories Inc is growing +1.0% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mesa Laboratories Inc (MLAB)?
Earnings per share at Mesa Laboratories Inc are growing −42.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Mesa Laboratories Inc (MLAB) carry?
The net debt of Mesa Laboratories Inc is $142M (fiscal year 2026, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Mesa Laboratories Inc in the live analysis

One click puts Mesa Laboratories Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.